On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell therapy for sickle cell disease (SCD). Eight of these patients have been dosed with BEAM-101, while the other enrolled patients are going through pre-transplant stages, including cell collection and drug product manufacturing. Also Read: Gene Editing Korro Bio’s Preclinical Data ‘Best-In-Class’, Analyst Initiates With Outperform Rating In a company presentation, preliminary safety data (N=6) showe…
